STOCK TITAN
  1. Home
  2. News
  3. SELB

Selecta Biosciences Inc - SELB STOCK NEWS

Welcome to our dedicated news page for Selecta Biosciences (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Selecta Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Selecta Biosciences's position in the market.

News
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Rhea-AI Summary
Cartesian Therapeutics, a clinical-stage biotechnology company (NASDAQ: RNAC), highlighted its recent progress and outlined 2024 strategic priorities across its pipeline of mRNA cell therapy product candidates. The company reported positive 12-month follow-up data from Phase 2a study of Descartes-08 in myasthenia gravis, with durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores. The company also announced the expansion of its clinical pipeline following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate. Cartesian ended 2023 with approximately $118M pro forma cash and cash equivalents, expected to support planned operations into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
-
News
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
Rhea-AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis (MG), a chronic autoimmune disorder. Descartes-08, an autologous anti-B-cell maturation antigen (BCMA) mRNA CAR-T, showed durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores without the need for lymphodepleting chemotherapy. The manuscript titled, 'Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy,' has been submitted for peer-review and can be accessed on the online preprint server, medRxiv. Topline data from a Phase 2b placebo-controlled study is expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
clinical trial
-
News
Selecta Biosciences Announces Merger with Cartesian Therapeutics
Rhea-AI Summary
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a merger with Cartesian Therapeutics, Inc., creating a publicly traded company pioneering RNA cell therapy for autoimmune diseases. The merger brings a pro forma cash balance of over $110 million, including $60.25 million from private financing, supporting the development of Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy for myasthenia gravis (MG), and additional RNA cell therapy programs. The combined company is expected to have multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG in mid-2024, and initiation of studies in additional autoimmune indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
acquisition
News
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
Rhea-AI Summary
Selecta Biosciences has entered into an agreement with Swedish Orphan Biovitrum AB (Sobi) to transition the manufacturing and development rights of ImmTOR for SEL-212. Sobi will assume responsibility for manufacturing and commercial supply starting November 6, 2023. The Biologics License Application (BLA) submission for SEL-212 is on track for the first half of 2024. Selecta employees supporting ImmTOR manufacturing and clinical development activities for SEL-212 are expected to become Sobi employees. Selecta is eligible to receive up to $615.0 million in milestone payments and royalties on net sales of SEL-212.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.2%
Tags
none
-
News
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
Rhea-AI Summary
Selecta Biosciences reports Q2 2023 financial results and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
earnings
-
News
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
clinical trial
News
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Selecta Biosciences reports positive Phase 3 data, plans capital prioritization initiative to extend cash runway
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
earnings
-
News
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Cellarity Strengthens Executive Leadership Team
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
management
News
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
clinical trial
Stock SELB logo
Selecta Biosciences Inc

Nasdaq:SELB

SELB Rankings

N/A Ranked by Market Cap
#3456 Ranked by Stock Gains
N/A Ranked by Dividends

SELB Stock Data

135.20M
94.00M
25.06%
47.78%
5.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Watertown

About SELB

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat